Take Your Trading To The Next Level. Get Started Here!

FDA approves GSK’s RSV vaccine for high-risk adults ages 50 to 59, expanding shot’s reach

June 7, 2024 Comments Off

The FDA’s expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.